Ocrelizumab is a medication used in the management and treatment of primary progressive and relapsing multiple sclerosis. It is in the anti-CD20 monoclonal antibody class of medications. This activity describes the indications, action, and contraindications for ocrelizumab as a valuable agent in multiple sclerosis management. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., administration, contraindications, monitoring, toxicity) pertinent for interprofessional team members in the care of patients with multiple sclerosis.

**Objectives:**
- Identify the mechanism of action of ocrelizumab.
- Describe the possible adverse effects of ocrelizumab.
- Review the toxicity of ocrelizumab.
- Summarize interprofessional team strategies for improving care coordination and communication to advance ocrelizumab and improve outcomes.